Targeting the immune checkpoints “programmed death ligand-1” (PD-L1), “programmed cell death protein-1” (PD-1) and “cytotoxic T-lymphocyte associated protein 4” (CTLA-4) with antibodies leads to T-cell activation and anti-tumor immune response [8]. This evidence concerns the gene PDCD1 and neoplasm.